Big congrats!!!

Excited to share our updated pre-clinical data on combination CD40 agonist + Flt3L + Doxil in breast cancer with Preteesh Leo Mylabathula MBBS, PhD, MS. UTSW Simmons Cancer Center #aacr24

#SABCS23 | Poster PO2-27-12 | Genomic determinants of benefit to nivolumab + low dose ipilimumab among patients with hypermutated HER2- #MBC : Results of #NIMBUS trial. #MetastaticBreastCancer Romualdo Barroso, MD PhD Sara Tolaney Nancy Lin, MD @nabihahtayob @emittendorfmd Rinath Jeselsohn Sangeetha Reddy

After my wonderful experience at MD Anderson Cancer Center, I've realized there is a robust academic life beyond it. Certainly, those who remain at or return to MDA also enjoy fulfilling careers. I've learned that various cancer centers contribute uniquely to breast cancer research.…

Tumor Agnostic Approaches to Care: Vivek Subbiah, MD, Joshua Z. Drago, Mia Levy, MD, PhD, and Marleen Kok addressed this topic in a Clinical Workshop moderated by Sangeetha M. Reddy this afternoon at #SABCS23 .
MarleenKokLab Sangeetha Reddy AACR UT Health San Antonio MD Anderson OncoAlert

Looking forward to moderating this session and hearing some stellar talks in Stars at Night Ballroom in just a few minutes! SABCS UTSW Simmons Cancer Center #sabcs23

Fantastic talk at #SITC2023 by Brekkenlab UTSW Simmons Cancer Center on Immune Regulation by Stromal Cells!

The cancer #immunity cycle provides a framework to understand the series of events that generate anti-cancer immune responses. Check out this revised review that helps better understand the successes & failures of cancer #immunotherapy doi.org/10.1016/j.immu…

It is not uncommon for clinician scientists to be questioned whether they’re ‘real doctors’ or ‘true scientists’

Both

The secret to a long life as a clinician scientist is the same as a long marriage. Selective deafness

Great paper ESMO Open Jon Lim
esmoopen.com/article/S2059-…

Highlighting the important role the innate immune system plays in immunotherapy, Sangeetha Reddy delivers an excellent lecture describing the rationale for augmenting CDK4/6i and ICB with dendritic cell therapy. #DAVAHawaiiBreast jitc.bmj.com/content/11/5/e…

Excited to share our work with Anna Vilgelm showing dendritic cell therapy augments anti-tumor immunity with CDK4/6i and immune checkpoint blockade!

jitc.bmj.com/content/11/5/e…

We did it! 7 mo of training, 9 days of hiking in the mountains, the hardest thing by far I’ve done to peak Mt Kilimanjaro…soaring above the clouds & making new family along the way…learned anything can be done by going pole pole (slow) one step at a time! An amazing experience!

Carlos L. Arteaga, M.D. Carlos: Thank you so much for the opportunity!

We have a post-doc position @utsw available! Please RT and DM me if interested in a position in translational breast tumor immunology and immunotherapy. We're doing very exciting work focused on enhancing antigen presentation. labs.utsouthwestern.edu/reddy-lab #postdocjobs

Incredible presentation at #SABCS2022 on InteractPrint by Student Doctor Lily Xu from Isaac Chan, MD, PhD Lab! Stellar mentorship by Dr. Chan to feature this rising star at a general session! Grateful for this incredible collaboration Sangeetha Reddy UTSW Simmons Cancer Center and excited for more to come!

PD1-blockade back in the game for ER+ breast cancer! 🎊Congrats to PACE trialists. 👏👏Impressive OS for pts treated with avelumab, most important no special tox in contrast to Cm7A8 and abema/pembro. aPD1 vs aPDL1? #sabcs22 . #bcsm SABCS

You don’t want to miss these sessions today! Sangeetha Reddy moderating “Modifying Tumor Response: Microbiome, Diet, and Fasting” from 1-2pm and Dr. Ariella Hanker presenting “Demystifying CDKs in Breast Cancer: Beyond CDK4/6” from 2-3pm at #SABCS22 . SABCS

Exciting talk by Isaac Chan, MD, PhD from UTSW Simmons Cancer Center on NK cells and dormancy as well as suppressive role of tumor reprogrammed NK cells at #SABCS22 !

Sorry the pun 🥸🤡, but for me this was RIGHTly the most interesting data from the 1st day of #SABCS22 .

Visceral crisis is a dramatic situation where chemo has always been the choice, but which ribo plus letrozole has shown to be more effective with less AEs
OncoAlert #bcsm

TALENT presented by Aditya Bardia, MD
Preop T-DXd +/- AI for ER+ HER2-low BC (6-8 cycles)
N=58

Response by imaging with T-DXd=68%, T-DXd+AI: 58%

1 pt with pCR, 5 with RCB1

16 pts still haven't had surgery

OncoAlert #bcsm #SABCS22